-
Surprise! Statins against liver cancer help develop new liver cancer drugs
Time of Update: 2021-01-06
these studies have shown that statin use can help improve HBV and HCV-related hepatocellular carcinoma (HCC).
In addition to inhibiting tumor cell flux, statins have been found to improve the potential mechanisms of hepatocellular carcinoma (HCC), tumor cell apoptosis, angiogenesis, tumor cell invasion, inflammation, liver fibrosis, and HCV pathogenis.
-
China's first "antibody drug coupled treatment of malignant tumor clinical application expert consensus" issued...
Time of Update: 2021-01-06
On December 5, China's first "Consensus of Experts on Clinical Application of Antibody Drug Associations for the Treatment of Malignant Tumors" was released at the National Cancer Center Clinical Res
-
Yingpai Pharmaceuticals Wee1 inhibitors are declared clinical in China
Time of Update: 2021-01-06
According to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China, Yingpai Pharmaceuticals submitted an application for a clinical trial in the study of Wee1 inhibitor IMP7068, which was accepted on December 7.
-
Research and development daily Rongchang bio-anti-HER2 antibody association drugs to be incorporated into the breakthrough treatment...
Time of Update: 2021-01-05
2020.12.17 Research and Development NEWS: Novo Nordis directly launched the 3700-person PHASE IIIa trial; Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical r
-
Hengrui Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical up to the main research...
Time of Update: 2021-01-05
On December 16th Henri Pharmaceuticals announced that the innovative drug, Carelli pearl monoantigen (Erika), had reached the end of two Phase 3 clinical studies: one for first-line treatment of advanced esophageal cancer with combined yew alcohol and cisplatin, and the other for first-line treatment of advanced or metastatic squamous non-small cell lung cancer patients with combined chemotherapy.
-
Chinese pharmaceutical companies rob the market for rare diseases! Asasin Pharma was awarded 8 orphan drug qualifications
Time of Update: 2021-01-05
PD-1/L1 inhibitor controversy intensified according to statistics, thought Di, and platinum medicine, cornerstone pharmaceutical industry, Junshi biological, Xinda biology, Baiji Shenzhou and other enterprises have PD-1/L1 inhibitors to obtain orphan drugs Qualifications, including nasopharyngeal cancer, T-cell lymphoma and other adaptations, in addition, Corning Jerry PD-L1/CTLA-4 double anti-KN046 treatment of thymus epithelial tumors also qualified by the FDA orphan drug.
-
Holding a number of pioneering drugs Deqi pharmaceutical by the capital market "wrong kill"?
Time of Update: 2021-01-05
number of patients with multiple myeloma in China 2019-2030 Source: Pharmaceutical Min-Juno Prospectus To expand the global commercial market for ATG-010, the company also plans to submit new drug listing applications for ATG-010 in Chinese mainland, Hong Kong, Taiwan, Australia, Singapore, South Korea and Thailand by 2021.
-
Amgen submits KRAS inhibitor AMG 51...
Time of Update: 2021-01-05
On December 16, Amgen announced that it had submitted to the FDA an application for the listing of KRASG12C inhibitor sotorasib (AMG 510) for the treatment of locally advanced or metastasis non-small cell lung cancer (NSCLC) with KRASG12C mutations that have been systematically treated at least once in the past.
-
A batch of non-base drugs is restricted in use
Time of Update: 2021-01-05
With the continuous reform of medical insurance payment methods such as payment by disease and total advance payment, from the point of view of ensuring supply and guiding clinical rational drug use, the guidance of the base drug catalogue will be stronger and stronger, which will promote the release of included varieties to a certain extent.
-
Injection consistency evaluation declaration "warming up" such enterprises and categories lead
Time of Update: 2021-01-05
Chart 3 Part of the injection data sources that have been evaluated by (or as if) consistency evaluation: CDE, company announcement, public information, China Health Industry Capital Research Center, updated to 2020.12.3 From the market size, the end-sales of over-evaluated injections in public medical institutions compared to the declared category higher, the adaptive category in addition to respiratory, digestive diseases, breast cancer, osteoblastoma and other anti-tumor injections also ranked in the category.
-
Huiyu pharmaceutical imitation 4 types of yew alcohol injection into the administrative approval stage
Time of Update: 2021-01-05
Yew alcohol product evaluation enterprise source: Mi net consistency evaluation database is currently listed in the domestic market yew alcohol products include yew alcohol injection, injection of yew alcohol lipids and injection of yew alcohol (albumin binding type).
-
Landmark clinical study TOP10 in 2020
Time of Update: 2021-01-05
In 2020, the pace of approval of new drugs by regulators such as the FDA and NMPA has not slowed, despite the global epidemic of new crown pneumonia. same time, some of the major clinical findings h
-
The world's top 10 pharmaceutical companies and the top 10 best-selling companies in 2021...
Time of Update: 2021-01-05
And evaluate predicts that even if Adamo monobial-like drugs are on the market, AbbVie's Shumeile remains the world's best-selling drug, and with the benefit of two popular new immunotherapy drugs, Rinvoq and Skyrizi, AbbVie is expected to add $6 billion in new sales next year, remaining the world's largest growing pharmaceutical company.
-
Nature: POLRMT variant inhibitors are effective
Time of Update: 2021-01-05
IMT inhibits tumor growth and mitochondrial gene expression in the body in a dose-dependent manner (Source: Nature) When studying the mechanism of the new inhibitors, the researchers observed that cancer cells were severely consumed with energy and nutrients when they were used.
-
Mercadon locks out TRACEr technology to develop next-generation T-cell therapy
Time of Update: 2021-01-04
The first generation of TCE triggers a systemic immune response that attacks not only tumors, but also healthy tissue, and the toxicity that can be life-threatening; not only limits the development of TCE, but also reduces the dose of drugs that can be used safely.
-
Microcore creatures
Time of Update: 2021-01-04
("Microcore Biotech") in the study of anti-tumor original innovative drug Chiauranib capsule by the State Drug Administration Drug Review Center (CDE) officially included in the "breakthrough treatment drug varieties", into the adaptation of the market approval as the target of confirmed Phase III clinical trials for the treatment of patients with progression or recurrence of small cell lung cancer (SCLC) after a 2-line system chemotherapy program.
-
Greenlee Pharmaceuticals and AstraZeneta are once again strategically working together to actively advance the cardiovascular and oncology sectors...
Time of Update: 2021-01-04
On December 28, 2020, Greenleaf Pharmaceutical Group and AstraZeneca signed a Memorandum of Strategic Cooperation, which will actively explore in-depth cooperation in the field of cardiovascular and oncology, focusing on green leaf pharmaceutical's natural drug hemolipid congen ®capsulates, in the field of oncology, innovative agent lipotin® and the anti-tumor biopharmaceutical beva bead monoantigen (LY01008) developed by Shandong Boan Biotechnology Co., Ltd., a subsidiary of Greenleaf Pharmaceuticals.
-
Anti-HER2 dual-specific antibody KN026 and Aibo new joint drug treatment program...
Time of Update: 2021-01-04
clinical trials have shown that KN026 has good tolerance and safety, and has significant anti-tumor activity in HER2-positive breast cancer patients who progress after multi-line anti-HER2 treatment.
-
"Pharmaceutical Speed Reading Society" 2020 Health Insurance Directory announced that the Ipaval single anti-is to be included in the priority ...
Time of Update: 2021-01-04
Negotiated drug price reduction average 50.64 percent; Xinlitai: proposed transfer of two product-related interests; Vidicido single resistance approved by CDE breakthrough treatment; Ipaval single resistance in China to be included in the priority review; Cyntafal pearl monoantitone in China approved treatment of relapsed glioblastoma ...
-
Research and development daily Xinda Beval bead monoantin resistance has been approved in China for the treatment of relapsed glioblastoma
Time of Update: 2021-01-04
2020.12.28 Research and Development NEWS: Cyndabava bead monoantigen resistance approved for the treatment of relapsed glioblastoma in China; Vidixito single resistance approved by CDE breakthrough treatment; Ipaval monoantigen in China to be included in priority review; anti-HER2 dual-specific antibody KN026 and Aibo new joint drug treatment program approved clinical ...
